Business Context and Reporting Period
This Form 8-K is a current report filed by Cocrystal Pharma, Inc. on January 4, 2019. The filing primarily addresses regulatory disclosures regarding upcoming investor meetings and a significant legal settlement involving a principal shareholder and director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on legal and disclosure events rather than periodic financial performance.
Material Changes and Events
- Regulation FD Disclosure: Senior executives are scheduled to hold meetings with the scientific and financial community beginning January 7, 2019. A corporate presentation (Exhibit 99.1) has been furnished for these meetings.
- SEC Settlement: Dr. Phillip Frost, a director and principal shareholder, entered into a settlement agreement with the SEC to resolve a complaint filed on September 7, 2018. Related entities, OPKO Health, Inc. and Frost Gamma Investments Trust, also settled.
- Settlement Terms: Dr. Frost agreed to pay approximately $5.5 million in penalties, disgorgement, and pre-judgment interest. He is enjoined from violating specific sections of the Securities Act and Exchange Act and is prohibited from trading in penny stocks, subject to exceptions.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking financial guidance or management commentary on operational outlook. The primary risk disclosed is the legal liability and financial penalty associated with the SEC action against Dr. Frost, which was resolved via settlement without an admission or denial of the allegations.
Investor Verification Checklist
- Verify the terms of the $5.5 million settlement agreement between Dr. Frost and the SEC.
- Review the corporate presentation (Exhibit 99.1) referenced in Item 7.01 for strategic updates.
- Confirm the impact of the settlement on Dr. Frost's role as a director and principal shareholder.
- Check for any subsequent filings regarding the court approval of the settlement.